REFERENCES
- Atkins P. Chlorofluorocarbon to hydrofluoroalkane formulations: An industry perspective. J Allergy Clin Immunol 1999; 104: S268–S270, [PUBMED], [INFOTRIEVE], [CSA]
- National Asthma Education and Prevention Program. Guidelines for the diagnosis and management of asthma. U.S. Department of Health and Human Services. National Institutes of Health, NIH Publication No. 97–4051, Bethesda, Maryland 1997
- Ayres J G, Millar A B, Sykes A P. Clinical efficacy and safety of fluticasone propionate 1 mg twice daily administered via a HFA-134a pressurized metered dose inhaler to patients with severe asthma. Respir Med 2000; 94(suppl B)S42–S50, [PUBMED], [INFOTRIEVE], [CSA]
- Tonnel A B, Bons J, Legendre M, Prud'Homme A, Bugnas B, Evano-Celli I, et al. Clinical efficacy and safety of fluticasone propionate 250 μg twice daily administered via a HFA-134a pressurized metered dose inhaler to patients with mild to moderate asthma. Respir Med 2000; 94(suppl B)S29–S34, [PUBMED], [INFOTRIEVE], [CSA]
- Perruchoud A P, Lundback B, Yigla M, Sikes A P. Clinical efficacy and safety of fluticasone propionate 1 mg per day administered via a HFA-134a pressurized metered-dose inhaler to patients with moderate to severe asthma. Respir Med 2000; 94(suppl B)S35–S41, [PUBMED], [INFOTRIEVE], [CSA]
- Flovent® 44 μg, 110 μg, 220 μg Inhalation Aerosol Package Insert. GlaxoSmithKline, , Research Triangle Park, NC March, 2004
- Szefler S J, Boushey H A, Pearlman D S, Togias A, Liddle R, Furlong A, et al. Time to onset of effect of fluticasone propionate in patients with asthma. J Allergy Clin Immunol 1999; 103: 780–788, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Pearlman D S, Stricker W, Weinstein S, Gross G, Chervinsky P, Woodring A, et al. Inhaled salmeterol and fluticasone: a study comparing monotherapy and combination therapy in asthma. Ann Allergy Asthma Immunol 1999; 82: 257–265, [PUBMED], [INFOTRIEVE], [CSA]
- Chervinsky P, van As A, Bronsky E A, Dockhorn R, Noonan M, LaForce C, et al. Fluticasone propionate aerosol for the treatment of adults with mild-to-moderate asthma. J Allergy Clin Immunol 1994; 94: 676–683, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Wolfe J D, Selner J C, Mendelson L M, Hampel F, Jr, Schaberg A. Effectiveness of fluticasone propionate in patients with moderate asthma: A dose-ranging study. Clin Ther 1996; 18: 635–646, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Galant S P, Lawrence M, Meltzer E O, Tomasko M, Baker K A, Kellerman D J. Fluticasone propionate compared with theophylline for mild-to-moderate asthma. Ann Allergy Asthma Immunol 1996; 77: 112–118, [PUBMED], [INFOTRIEVE], [CSA]
- Sheffer A L, LaForce C, Chervinsky P, Pearlman D, Schaberg A. Fluticasone propionate aerosol: Efficacy in patients with mild-to-moderate asthma. J Fam Pract 1996; 42: 369–375, [PUBMED], [INFOTRIEVE], [CSA]
- Noonan M J, Chervinsky P, Wolfe J, Liddle R, Kellerman D J, Crescenzi K L. Dose-related response to inhaled fluticasone propionate in patients with methacholine-induced bronchial hyperresponsiveness: A double-blind, placebo-controlled study. J Asthma 1998; 35: 153–164, [PUBMED], [INFOTRIEVE], [CSA]
- Cripps A, Riebe M, Schulze M, Woodhouse R. Pharmaceutical transition to non-CFC pressurized metered dose inhalers. Respir Med 2000; 94(suppl B)S3–S9, [PUBMED], [INFOTRIEVE], [CSA]
- Li J T, Ford L B, Chervinsky P, Weisberg S C, Kellerman D J, Faulkner K G, et al. Fluticasone propionate powder and lack of clinically significant effects on hypothalamic-pituitary-adrenal axis and bone mineral density over 2 years in adults with mild asthma. J Allergy Clin Immunol 1999; 103: 1062–1068, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Kemp J P, Osur S, Shrewsbury S B, Herje N E, Duke S P, Harding S M, et al. Potential effects of fluticasone propionate on bone mineral density in patients with asthma: A 2-year randomized, double-blind, placebo-controlled trial. Mayo Clin Proc. 2004; 79(4)458–466, [PUBMED], [INFOTRIEVE], [CSA]